This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779312

WORK PACKAGE 10

Country Vignettes

As part of WP10 – Appraisal of orphan medicinal products, HTA appraisal/reimbursement processes for rare disease treatments in most EU and EEA Member States, Canada and New Zealand have been documented.

 

These country vignettes are now publicly available and can be found in the list below. More information on how this was done can also be found in the background document below.

BACKGROUND [PDF]

Click on a flag to download the country vignette [PDF}

Austria

Austria

Belgium

Belgium

Bulgaria

Bulgaria

Canada

Canada

Czech Republic

Czech Republic

Denmark

Denmark

Estonia

Estonia

Finland

Finland

France

France

Germany

Germany

Hungary

Hungary

Iceland

Iceland

Ireland

Ireland

Italy

Italy

Latvia

Latvia

Liechtenstein

Liechtenstein

Lithuania

Lithuania

Malta

Malta

Netherlands

Netherlands

New Zealand

New Zealand

Norway

Norway

Poland

Poland

Portugal

Portugal

Romania

Romania

Slovakia

Slovakia

Slovenia

Slovenia

Sweden

Sweden

Switzerland

Switzerland

UK/England

UK/England

UK/Scotland

UK/Scotland

Leads

Università Commerciale Luigi Bocconi

 

University of Edinburgh

Principal Investigators

Karen Facey

Elena Nicod